Skip to main content

Advertisement

Advertisement

ADVERTISEMENT

Conference Coverage

Dupilumab Is Even More Effective at Treating Atopic Dermatitis in a Real World Setting

John Otrompke, BA, JD

Dupilumab is even more effective at treating both adults and children with atopic dermatitis (AD) in the real world than clinical research data suggest, according to a single center chart review. Of adult patients, 93% reported at least partial remission (92% for pediatric patients. These data are being presented at the 2022 American Academy of Dermatology Annual Meeting).

“In clinical trials, between 50% and 60% of patients with atopic dermatitis treated with dupilumab for one year achieved success defined by an Investigator’s Global Assessment score of 0 or 1 or improvement in the Eczema Area and Severity Index of at least 75%... In treating [AD], clinical efficacy- determined by the stringent definitions of ‘success’ used in clinical trials- may not accurately reflect real world clinical success rates,” wrote lead author Veronica Emmerich, BA, Wake Forest School of Medicine, Winston-Salem, North Carolina, and co-authors.

Researchers analyzed data from the charts of 98 adult patients (ages 18-85) and 24 pediatric patients (ages 9-17) seen at Wake Forest Baptist Health between 2017 and 2020. Of adults, 40% experienced complete remission.

Among adult patients, 22 experienced side effects, conjunctivitis (n=12) being the most common. Among pediatric patients, 6 experienced side effects such as conjunctivitis (n=3) and facial redness (n=1).

Issues with insurance or cost led 3 pediatric patients to discontinue treatment, while 5 adult patients discontinued for that reason. A total of 23 adult patients discontinued treatment; other reasons included side effects (n=8), no improvement (n=4), complete disease remission (n=2), and other reasons (n=4).

Reference
Emmerich V, Williams J, Hrin M, et al. Real-world effectiveness of dupilumab for the treatment of atopic dermatitis in adult and pediatric patients. Poster presented at: AAD Annual Meeting; March 25-29, 2022. Boston, MA.

Advertisement

Advertisement

Advertisement